ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?
ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell? The Globe and Mail
Covered in this story
Analyst targets on AbbVie
- UBS: at $276 · target $275 by Oct 2027 · Neutral via GuruFocus
- Bank of America: at $262 · target $289 by Sep 2027 · Buy via AOL.com
- Wolfe Research: at $263 · target $300 by Sep 2027 · Outperform via Yahoo Finance
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 49 stories mentioning AbbVie, the earliest published 1 Dec 2017.
Summary aggregated from The Globe and Mail's public RSS feed. The full reporting belongs to The Globe and Mail — please read it on their site.